This content has been independently produced by ADG, made possible through sponsorship from Amgen

The results of a US study that show rapid LDL-C lowering within one day in patients who were given the PCSK9 inhibitor, evolocumab shortly after a heart attack “may reframe what we are able to do with our patients”, according to an Australian cardiologist.

Dr Warrick Bishop (pictured) says the EVACS trial published in Circulation “gives us a glimpse of how PCSK9 inhibitors may be used in the future as an initial treatment strategy for acute coronary syndrome (ACS) based on efficacy and tolerability, and rapid results”.

“It’s a tantalising concept. A jab in the thigh as the patient hits the door means they are starting their secondary prevention journey immediately and effectively,” says Dr Bishop who specialises in CVD prevention and lipid management at his Hobart practice.